[ad_1]
Tip Ranks
These 3 penny stocks could rise by more than 100%, Roth Capital says
Does high risk mean high reward? Not necessarily, so the Wall Street professionals say. Specifically citing penny stocks, or stocks that are trading for under $ 5 per share, analysts advise caution as these names may still be at the start of the inning, or it could be that they are facing an uphill battle that is simply too steep. Price tags torn apart, these stocks may face oppressive headwinds or have weak fundamentals.However, analysts argue that there are early stage companies that reflect promising opportunities, with low stock prices meaning you get a lot more. bang for your dollar. Furthermore, even what appears to be a minor appreciation in the stock price can lead to huge percentage gains. Not all risks are created equal. To this end, professionals recommend doing some due diligence before making an investment decision. With that in mind, we turned to investment firm Roth Capital for some inspiration. The firm’s analysts spotted three attractive penny stocks, noting that each could rise by more than 100% in the year ahead. Using the TipRanks database, we discovered what makes all three plays so exciting even with the risk involved. CohBar (CWBR) Focused on the development of mitochondria-based therapies (MBT), CohBar aims to find new treatments for diseases associated with aging and metabolic dysfunction. Based on the strength of its technology and its $ 0.96 share price, Roth Capital thinks now is the time to pull the trigger. Writing for the company, analyst Elemer Piros points out that CWBR was able to transform over 100 mitochondrial peptides into 1,000 mitochondrial ones. based therapy (MBT). Scientists and researchers from the company around the world have found that mitochondrial peptides regulate multiple physiological systems, including the risk factors that lead to cardiovascular and neurodegenerative diseases, obesity, diabetes, fatty liver disease, fibrotic and inflammatory diseases, and cancer. It should be noted that peptides are released continuously or intermittently to modulate biological functions, but it is difficult to administer them as therapies. Furthermore, they also tend to have a shorter half-life. “CohBar has developed methods for modifying peptides and plans to use modified analogs for clinical development,” commented Piros. The first for CWBR is CB4211, its optimized analog of the mitochondrial derived peptide MOTS-c. The company’s first clinical candidate is concluding a Phase 1b study in patients with fatty liver disease. According to management, there are 10 patients who will be randomized to CB4211 treatment and 10 to placebo, with results expected in the first quarter of 2021 Nonalcoholic fatty liver disease (NAFLD) is a condition defined by the excessive accumulation of fat in the form of triglycerides (steatosis) in the liver in people who consume little or no alcohol. Additionally, the company will also target non-alcoholic steatohepatitis (NASH), which is the most severe form of NAFLD. Piros acknowledges that competition in space is fierce, but says “the winners cannot yet be identified”. Exposing this, the analyst said, “CB4211 offers an as yet unexplored mechanism of action, which is fundamental, based on the natural control of homeostasis, which is lost due to environmental or genetic insults. The compound was derived from naturally occurring mitochondrial peptides, with the aim of restoring and rebalancing homeostasis with the aim of reversing pathological processes. Based on the above, Piros sees an attractive risk / return in CWBR shares. “[We] CohBar value based on a comparable universe of early and mid-stage companies with platforms that could produce more drug candidates. The average corporate value of this group of companies is $ 268 million compared to CohBar at $ 38 million. We anticipate that CohBar shares could trade in line with the average, “concluded the analyst. To this end, Piros values CWBR as a Buy along with a price target of $ 8. If his thesis were to end, a potential gain 12-month stock of 741% may be in the cards. (To see Piros’ track record, click here) Overall, CWBR has a small, but noisy group of bullish analysts with positive expectations for its stock. Of the 2 analysts surveyed. from TipRanks, they both rate the stock as Buy. With a potential return of 557%, the stock’s consensus price target is $ 6.25. (See CWBR stock analysis on TipRanks) Eyenovia (EYEN) Using his Patented piezo-printed delivery technology, Eyenovia is developing a pipeline of micro-dose therapies. With shares changing hands for $ 3.41 each, Roth Capital sees an attractive entry point for investors. In October, Eyenovia announces that an affiliate of Bausch Health Companies had acquired an exclusive license in the United States and Canada for the experimental microdose formulation of Atropine Ophthalmic Solution (MicroPine), designed to reduce the progression of myopia in children aged 3 and 12 years. MicroPine, which is supplied via EYEN’s proprietary Optejet regulator, is proceeding through Phase 3, with launch potentially coming in 2025 Under the terms of the agreement, Bausch will assume the supervision and expenses related to the ongoing CHAPERONE trial Phase 3. In turn, Eyenovia will receive an upfront payment of $ 10 million and up to $ 35 million of approval and launch-based milestones, along with royalties ranging from gross profit percentages on sales in the United States and Canada, half to single digit to half adolescent. Capital’s Jonathan Aschoff tells clients that “the deal validates the technology and the market.” He adds that this deal and the recent Asian MicroPine deal with Arctic Vision, “combined with the approximately $ 25 million in R&D savings for EYEN that these two deals provide, should improve EYEN’s cash flow by approximately $ 100 million in sales. next years”. To that end, he argues that the company’s cash position should support its operations in 1H22.On top of that, assuming there are no COVID-related delays, Aschoff believes EYEN should be able to initiate both trials. VISION Phase 3 for MicroLine, its pilocarpine piezoelectric formulation designed to replace reading glasses for three to four hours while addressing the instillation and tolerability issues associated with traditional eye drops, by YE20. This means the trials will be able to sign up in a few weeks, and the results could be published in 2021. If that’s not enough, the company is planning to roll out the NDA MicroStat (its mydriasis candidate) by YE20, with the U.S. launch potentially coming in late 2021. “Commercialization of MicroStat should be helped by the current pandemic, as clinicians are more reluctant than ever to reuse the same dropper for multiple patients, and with reuse generally encompassing around 20- 30 patients, the dropper alone has become about 20-30 times more expensive for the physician, ”Aschoff explained. It should come as no surprise, then, that Aschoff left a buy rating and $ 11 price target on the stock. Given this target, stocks could rise 223% over the next year. (To see Aschoff’s track record, click here) Looking at the breakdown of consent, there have been 2 purchases issued and no suspensions or sales in the last three months. Therefore, EYEN obtains a moderate purchase consent rating. Based on the average price target of $ 8.50, the stock could earn 150% in the coming months. (See EYEN Stock Analysis on TipRanks) Boqii Holding (BQ) Last but not least we have Boqii Holding, which operates the largest online pet products platform in China, with its primary focus on online retail through third-party Chinese online platforms and its own e-commerce site (Boqii Mall). Currently priced at $ 4.45 each, Roth Capital believes its share price represents an opportunity to get in on the action. Representing the company, analyst Darren Aftahi told clients, “BQ represents an early stage opportunity for investors to gain exposure to everything related to pets, which uniquely blends” community “and” trade “in a vertical and offline omnichannel platform”. Part of what makes BQ so interesting is that while it operates primarily as an e-commerce company, it boasts a verticalized omnichannel platform for pet products, according to Aftahi. Additionally, the company has integrated into offline channels such as pet stores and hospitals. The analyst argues that this not only expands consumer access points, but the online community also keeps users engaged with various forms of content and marketing, “increasing the overall value of the platform for end customers.” According to Frost & Sullivan, China’s pet population growth is projected to be among the fastest in the coming years, with US ownership (400 million pets) expected to equal US ownership (400 million pets) by 2024 by about a third of the current rate. “We believe BQ can see accelerated growth when we focus on continued adoption of e-commerce spending, with pet retail spending expected to reach 52% of total pet retail. by 2024, “Aftahi commented. It should be noted that over 60% of sales come from BQ stores on third-party sites such as Tmall, JD.com and Pinduoduo, which according to Aftahi “broadens the reach of the BQ brand”. Offering further explanation, the analyst said, “These sites are often the initial point of contact and users can then be funneled into BQ’s online community for re-targeting, giving BQ an edge in client ownership. point of view, BQ is set to capture the growth from the shift to e-commerce, diversified in access points, but under the BQ brand regardless. ”Everything BQ has done has prompted Aftahi to maintain its purchase valuation as is. Along with the call, leave the price target at $ 10, suggesting upside potential of 123%. (To see Aftahi’s track record, click here) When it comes to other analyst activity, it’s rest assured. As Aftahi is the only analyst who posted a review recently. (See BQ Stock Analysis on TipRanks) To find good ideas for trading penny stocks at attractive valuations, visit TipRanks’ Best Stocks to Buys , one str Just launched raise that combines all of TipRanks’ equity insights. only those of the analysts present. The content is to be used for informational purposes only. It is very important to do your own analysis before making any investments.
